Health Canada has authorized the single-shot COVID-19 vaccine of Janssen, a Johnson & Johnson (JNJ) company, to prevent COVID-19 in individuals aged 18 years and older.  Health Canada’s authorization was based on the scientific evidence provided by the company, which included initial data from the Phase 3 ENSEMBLE study. The data demonstrated the efficacy of the vaccine at 85% in preventing the disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.  Notably, the Phase 3 ENSEMBLE study was designed to evaluate the safety and efficacy of the company’s vaccine in protecting against both moderate and severe COVID-19 disease.
https://www.tipranks.com/news/health-canada-approves-johnson-johnsons-covid-19-vaccine?utm_source=advfn.com&utm_medium=referral